Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 47 of 720 for:    Botulinum Toxins, Type A

Efficacy and Safety of Clostridium Botulinum Toxin Type A to Improve Appearance of Moderate to Severe Glabellar Lines (BTX-A-HAC NG)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02353871
Recruitment Status : Completed
First Posted : February 3, 2015
Results First Posted : October 2, 2017
Last Update Posted : December 15, 2017
Sponsor:
Information provided by (Responsible Party):
Ipsen

Brief Summary:
The purpose of this study was to demonstrate the safety and the efficacy of a single treatment of an injectable liquid form of Clostridium botulinum toxin type A haemagglutinin complex (BTX-A-HAC; hereafter referred to as BTX-A-HAC Next Generation (BTX-A-HAC NG)), used for the improvement in the appearance of moderate to severe glabellar lines (the lines between the eyebrows).

Condition or disease Intervention/treatment Phase
Moderate to Severe Glabellar Lines Drug: Clostridium Botulinum Toxin Type A Drug: Placebo Phase 3

Detailed Description:

At the Baseline Visit (Day 1), subjects were randomised in a ratio of 2:1 to receive either BTX-A-HAC NG solution (50 U) or placebo. Randomisation was stratified according to gender and severity of glabellar lines at maximum frown (moderate to severe) at Baseline. A single dose of BTX-A-HAC NG solution 50 U or placebo was injected on Day 1. Subjects were then monitored at the study centre for 30 minutes. On Day 4, subjects were contacted by telephone for adverse event monitoring and to record concomitant medications and treatments.

Subjects attended follow-up visits at the study centre on Days 8, 15, 29, 57, 85, 113, 148 and 183. The Day 183 follow-up visit was the end of study visit; all subjects who had completed the Day 183 Visit were considered to have completed the study.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 185 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase III, Double Blind, Randomised, Placebo Controlled Study To Assess The Efficacy And Safety Of A Single Treatment Of Clostridium Botulinum Toxin Type A To Improve The Appearance Of Moderate To Severe Glabellar Lines
Study Start Date : January 2015
Actual Primary Completion Date : April 2015
Actual Study Completion Date : August 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Botox

Arm Intervention/treatment
Experimental: BTX-A-HAC NG
Clostridium Botulinum Toxin Type A (BTX-A-HAC NG) 50 Unit (U) solution, single dose (intramuscular injection). The total treatment volume (0.25 mL) was divided into five injections (0.05 mL per injection) injected in five predefined sites across the glabellar region. A total of 50 U was injected.
Drug: Clostridium Botulinum Toxin Type A
A solution containing 50 U in 0.25 mL (200 U/mL). Each vial contained 0.625 mL of deliverable volume of solution. A volume of 0.25 mL, containing 50 U of BTX-A-HAC NG (i.e. 10 U/0.05 mL) was withdrawn from the vial into a syringe for administration. The total treatment volume (0.25 mL) was divided into five injections (0.05 mL per injection), each of which was to be administered into predefined sites across the glabellar region (two injections into each corrugator muscle and one injection into the procerus muscle).
Other Names:
  • Botulinum Toxin Type A
  • BTX-A-HAC NG

Placebo Comparator: Placebo
Single dose (intramuscular injection). The total placebo volume (0.25 mL) was divided into five injections (0.05 mL per injection) injected in five predefined sites across the glabellar region.
Drug: Placebo
A solution containing only the excipients of BTX-A-HAC NG (identical in appearance to the active product). Each vial contained 0.625 mL of deliverable volume of solution. A volume of 0.25 mL was withdrawn from the vial into a syringe for administration. The total treatment volume (0.25 mL) was divided into five injections (0.05 mL per injection), each of which was to be administered into predefined sites across the glabellar region (two injections into each corrugator muscle and one injection into the procerus muscle).




Primary Outcome Measures :
  1. The Proportion of Responders at Day 29 in the ILA of Glabellar Lines at Maximum Frown. [ Time Frame: Day 29 ]

    ILA

    4-point photographic scale: None - Grade 0; mild - Grade 1; moderate - Grade 2; severe - Grade 3.

    A responder at maximum frown was defined as having a severity grade of none (Grade 0) or mild (Grade 1) at maximum frown on Day 29 and a severity grade of moderate (Grade 2) or severe (Grade 3) at Baseline (Day 1).

    The adjusted proportion of responders in each treatment group was provided using a multivariate logistic regression model.



Secondary Outcome Measures :
  1. The Proportion of Responders at Each Post-treatment Visit to the Study Centre (Except Day 29) as Measured by the ILA at Maximum Frown. [ Time Frame: Day 8, 15, 57, 85, 113, 148 and 183 ]

    ILA

    4-point photographic scale: None - Grade 0; mild - Grade 1; moderate - Grade 2; severe - Grade 3.

    A responder at maximum frown was defined as having a severity grade of none (Grade 0) or mild (Grade 1) at maximum frown at a given visit and a severity grade of moderate (Grade 2) or severe (Grade 3) at Baseline (Day 1).

    The adjusted proportion of responders in each treatment group was provided using a multivariate logistic regression model.


  2. The Proportion of Responders on Day 29 Who Remained Responders on Days 57, 85, 113, 148 and 183 as Measured by the ILA at Maximum Frown. [ Time Frame: Day 57, 85, 113, 148 and 183 ]

    ILA

    4-point photographic scale: None - Grade 0; mild - Grade 1; moderate - Grade 2; severe - Grade 3.

    A responder at maximum frown was defined as having a severity grade of none (Grade 0) or mild (Grade 1) at maximum frown at a given visit and a severity grade of moderate (Grade 2) or severe (Grade 3) at Baseline (Day 1). Subjects who were not responders at Day 29 were excluded from the analysis.

    The adjusted proportion of responders in each treatment group was provided using a multivariate logistic regression model.


  3. The Proportion of Responders at Each Post-treatment Visit to the Study Centre as Measured by the ILA at Rest. [ Time Frame: Day 8, 15, 29, 57, 85, 113, 148 and 183 ]

    ILA

    4-point photographic scale: None - Grade 0; mild - Grade 1; moderate - Grade 2; severe - Grade 3.

    A responder at rest was defined as having a severity grade of none (Grade 0) or mild (Grade 1) at rest at a given visit and a severity grade of moderate (Grade 2) or severe (Grade 3) at Baseline (Day 1).

    The adjusted proportion of responders in each treatment group was provided using a multivariate logistic regression model.


  4. The Proportion of Subjects With a Reduction of Two or More Grades in the Severity of Glabellar Lines at Each Post-treatment Visit to the Study Centre as Measured by the ILA at Maximum Frown. [ Time Frame: Day 8, 15, 29, 57, 85, 113, 148 and 183 ]

    ILA

    4-point photographic scale: None - Grade 0; mild - Grade 1; moderate - Grade 2; severe - Grade 3.

    Adjusted proportion of subjects with a reduction of two or more grades in the severity of glabellar lines at each post-treatment visit compared with Baseline.

    The adjusted proportion of responders in each treatment group was provided using a multivariate logistic regression model.


  5. The Proportion of Responders at Each Post-treatment Visit to the Study Centre as Measured by the Subject's Self-assessment (SSA) at Maximum Frown. [ Time Frame: Day 8, 15, 29, 57, 85, 113, 148 and 183 ]

    SSA

    4-point photographic scale: No wrinkles - 0; Mild wrinkles - 1; Moderate wrinkles - 2; Severe wrinkles - 3.

    A responder at maximum frown was defined as having a severity grade of no wrinkles (Grade 0) or mild wrinkles (Grade 1) at maximum frown at a given visit and a severity grade of moderate wrinkles (Grade 2) or severe wrinkles (Grade 3) at Baseline (Day 1).

    The adjusted proportion of responders in each treatment group was provided using a multivariate logistic regression model.


  6. The Proportion of Responders at Each Post-treatment Visit to the Study Centre as Measured by the Subject's Level of Satisfaction With the Appearance of Their Glabellar Lines. [ Time Frame: Day 8, 15, 29, 57, 85, 113, 148 and 183 ]

    Adjusted proportion of responders at each post-treatment visit (measured by the subject's level of satisfaction with the appearance of their glabellar lines).

    4-point categorical scale: Grade 0 - very satisfied; Grade 1 - satisfied; Grade 2 - dissatisfied; Grade 3 - very dissatisfied.

    A responder was defined as having a satisfaction rating of very satisfied (Grade 0) or satisfied (Grade 1) at a given visit and a satisfaction rating of dissatisfied (Grade 2) or very dissatisfied (Grade 3) at Baseline (Day 1).

    The adjusted proportion of responders in each treatment group was provided using a multivariate logistic regression model.


  7. The Time to Onset of Treatment Response Based on the Subject's Diary Card. [ Time Frame: Day 1 to 7 ]
    Median time to onset of treatment response: subjects asked to record their assessment of study treatment response in a diary card on Days 1 to 7. They responded 'yes' or 'no' to the following question: 'since being injected have you noticed an improvement in the appearance of your glabellar lines (lines between your eyebrows)?'



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Provision of written informed consent prior to any study related procedures.
  2. Male or female between 18 and 65 years of age, inclusive.
  3. Had moderate or severe (Grade 2 or 3) vertical glabellar lines at maximum frown at baseline (Day 1), as assessed by the ILA using a validated 4-point photographic scale.
  4. Had moderate or severe (Grade 2 or 3) vertical glabellar lines at maximum frown at baseline (Day 1), as assessed by the SSA using a validated 4-point categorical scale.
  5. Were dissatisfied or very dissatisfied (Grade 2 or 3) with their glabellar lines at baseline (Day 1), as assessed by the subject's level of satisfaction.
  6. Had a negative pregnancy test (for females of childbearing potential only). Nonchildbearing potential was defined as post menopausal for at least 1 year, surgical sterilisation at least 3 months before entering the study, or hysterectomy.
  7. Had both the time and the ability to complete the study and comply with study instructions.

Exclusion Criteria:

  1. Previous treatment with any serotype of botulinum toxin (BTX).
  2. Any prior treatment with permanent fillers in the upper face including the glabellar lines area.
  3. Any prior treatment with long lasting dermal fillers in the upper face including the glabellar lines area within the past 3 years and/or skin abrasions/resurfacing (whatever the interventional technic used) within the past 5 years, or photorejuvenation or skin/vascular laser intervention within the past 12 months.
  4. Any planned facial cosmetic surgery during the study.
  5. A history of eyelid blepharoplasty or brow lift within the past 5 years.
  6. An inability to substantially reduce glabellar lines by physically spreading them apart or lack of capacity to frown.
  7. An active infection or other skin problems in the upper face including the glabellar lines area (e.g. acute acne lesions or ulcers).
  8. Use of concomitant therapy which, in the Investigator's opinion, would have interfered with the evaluation of the safety or efficacy of the study treatment, including medications affecting bleeding disorders (antiplatelet agents and/or anticoagulants given for treatment or prevention of cardiovascular/cerebrovascular diseases).
  9. Pregnant women, nursing mothers, or women who were planning a pregnancy during the study, or believed they may be pregnant at the start of the study. Throughout the course of the study, women of childbearing potential had to use a reliable form of contraception (e.g. oral contraceptives for more than 12 consecutive weeks, or spermicide and condoms).
  10. A history of drug or alcohol abuse.
  11. Treatment with an experimental drug or use of any experimental device within 30 days prior to the start of the study and during the conduct of the study.
  12. Known allergy or hypersensitivity to any serotype of BTX or any component of BTX-A-HAC NG.
  13. Clinically diagnosed significant anxiety disorder, or any other significant psychiatric disorder (e.g. depression) that might interfere with the subject's participation in the study.
  14. Use of medications that affect neuromuscular transmission, such as curare like nondepolarising agents, lincosamides, polymyxins, anticholinesterases and aminoglycoside antibiotics, within the past 30 days.
  15. A history of facial nerve palsy.
  16. Marked facial asymmetry, ptosis, excessive dermatochalasis, deep dermal scarring, or thick sebaceous skin.
  17. The presence of any other condition (e.g. neuromuscular disorder or other disorder that could interfere with neuromuscular function), laboratory finding or circumstance that, in the judgement of the Investigator, might increase the risk to the subject or decrease the chance of obtaining satisfactory data to achieve the objectives of the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02353871


Locations
Layout table for location information
France
Nouvelle Clinique Bel Air
Bordeaux, France, 33200
Cabinet Medical
Cannes, France, 06400
Mediti
Juan les Pins, France, 06160
Clinique IENA
Paris, France, 75116
Germany
Rzany & Hund Privatpraxis für Dermatologie
Berlin, Germany, 10707
Medical Skin Center
Düsseldorf, Germany, 40212
University of Hamburg
Hamburg, Germany, 20146
Rote Kreuz Krankenhaus
Kassel, Germany, 34121
Hautzentrum am Starnberger See
Starnberg, Germany, 82319
Sponsors and Collaborators
Ipsen
Investigators
Layout table for investigator information
Study Director: Ipsen Study Director Ipsen

Layout table for additonal information
Responsible Party: Ipsen
ClinicalTrials.gov Identifier: NCT02353871     History of Changes
Other Study ID Numbers: Y-52-52120-189
2013-002321-34 ( EudraCT Number )
First Posted: February 3, 2015    Key Record Dates
Results First Posted: October 2, 2017
Last Update Posted: December 15, 2017
Last Verified: November 2017

Keywords provided by Ipsen:
Moderate to Severe

Additional relevant MeSH terms:
Layout table for MeSH terms
Botulinum Toxins
Botulinum Toxins, Type A
abobotulinumtoxinA
Acetylcholine Release Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Cholinergic Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Neuromuscular Agents
Peripheral Nervous System Agents